Skip to main content
Erschienen in: Journal of Endocrinological Investigation 12/2015

01.12.2015 | Original Article

Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression

verfasst von: F. Rosignolo, V. Maggisano, M. Sponziello, M. Celano, C. R. T. Di Gioia, M. D’Agostino, L. Giacomelli, A. Verrienti, M. Dima, V. Pecce, C. Durante

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Down-regulation of thyroid hormone receptor beta (THRβ) gene has been described in several human malignancies, including thyroid cancer. In this study, we analyzed THRβ mRNA expression in surgical specimens from a series of human papillary thyroid carcinomas (PTCs), characterized by their genotypic and clinical–biological features.

Methods

Thirty-six PTCs were divided into two groups according to the 2009 American Thyroid Association risk classification (17 low, 19 intermediate), and each group was divided into subgroups based on the presence or absence of the BRAFV600E mutation (21 BRAF mutated, 15 BRAF wild type). Gene expression was analyzed using fluidic cards containing probes and primers specific for the THRβ gene, as well as for genes of thyroperoxidase (TPO), sodium/iodide symporter (NIS), thyroglobulin (Tg) and thyroid stimulating hormone receptor (TSH-R) and for some miRNAs involved in thyroid neoplasia and targeting THRβ. The mRNA levels of each tumor tissue were compared with their correspondent normal counterpart.

Results

THRβ transcript was down-regulated in all PTCs examined. No significant differences were found between intermediate- vs low-risk PTCs patients, and BRAF-mutated vs BRAF wild-type groups. THRβ expression was directly correlated with NIS, TPO, Tg and TSH-R, and inversely correlated to miR-21, -146a, -181a and -221 expression.

Conclusions

Our results demonstrate that down-regulation of THRβ is a common feature of PTCs. While it is not associated with a more aggressive phenotype of PTC, it correlates with the reduction of all the markers of differentiation and is associated with overexpression of some miRNAs supposed to play a role in thyroid tumorigenesis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Cheng SY (2000) Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord 1:9–18CrossRefPubMed Cheng SY (2000) Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. Rev Endocr Metab Disord 1:9–18CrossRefPubMed
3.
Zurück zum Zitat Li Z, Meng ZH, Chandrasekaran R, Kuo WL, Collins CC, Gray JW, Diarkee SH (2002) Biallelic inactivation of the thyroid hormone receptor β1 gene in early stage breast cancer. Cancer Res 62:1939–1943PubMed Li Z, Meng ZH, Chandrasekaran R, Kuo WL, Collins CC, Gray JW, Diarkee SH (2002) Biallelic inactivation of the thyroid hormone receptor β1 gene in early stage breast cancer. Cancer Res 62:1939–1943PubMed
4.
Zurück zum Zitat Ling Y, Xu X, Hao J, Ling X, Du X, Liu X, Zhao X (2010) Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients. Cancer Genet Cytogenet 196:140–145CrossRefPubMed Ling Y, Xu X, Hao J, Ling X, Du X, Liu X, Zhao X (2010) Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients. Cancer Genet Cytogenet 196:140–145CrossRefPubMed
5.
Zurück zum Zitat Lin KH, Shieh HY, Chen SL, Hsu HC (1999) Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 26:53–61CrossRefPubMed Lin KH, Shieh HY, Chen SL, Hsu HC (1999) Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 26:53–61CrossRefPubMed
6.
Zurück zum Zitat Futreal PA, Cochran C, Marks JR, Iglehart JD, Zimmerman W, Barret JC, Wiseman RW (1994) Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line. Cancer Res 54:1791–1794PubMed Futreal PA, Cochran C, Marks JR, Iglehart JD, Zimmerman W, Barret JC, Wiseman RW (1994) Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line. Cancer Res 54:1791–1794PubMed
7.
Zurück zum Zitat Dobrovic A, Houle B, Belouchi A, Bradley WE (1988) erbA-related genes coding for DNA-binding hormone receptors localized to chromosome 3p21-3p25 and deleted in small cell lung carcinoma. Cancer Res 48:682–685PubMed Dobrovic A, Houle B, Belouchi A, Bradley WE (1988) erbA-related genes coding for DNA-binding hormone receptors localized to chromosome 3p21-3p25 and deleted in small cell lung carcinoma. Cancer Res 48:682–685PubMed
8.
Zurück zum Zitat Sisley K, Kurtis D, Rennie IG, Rees RC (1993) Loss of heterozygosity of the thyroid hormone receptor β in posterior uveal melanoma. Melanoma Res 3:457–461CrossRefPubMed Sisley K, Kurtis D, Rennie IG, Rees RC (1993) Loss of heterozygosity of the thyroid hormone receptor β in posterior uveal melanoma. Melanoma Res 3:457–461CrossRefPubMed
9.
Zurück zum Zitat Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, Regadera J, Larcher F, Paramio JM, Vennström B, Aranda A (2009) Thyroid hormone receptor β1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res 69(2):501–509CrossRefPubMed Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, Regadera J, Larcher F, Paramio JM, Vennström B, Aranda A (2009) Thyroid hormone receptor β1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res 69(2):501–509CrossRefPubMed
10.
Zurück zum Zitat Kim WG, Zhu X, Kim DW, Zhang L, Kebebew E, Cheng SY (2013) Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression. Endocrinology 154:25–35PubMedCentralCrossRefPubMed Kim WG, Zhu X, Kim DW, Zhang L, Kebebew E, Cheng SY (2013) Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression. Endocrinology 154:25–35PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Zhu XG, Zhao L, Willingham MC, Cheng SY (2010) Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma. Oncogene 29:1909–1919PubMedCentralCrossRefPubMed Zhu XG, Zhao L, Willingham MC, Cheng SY (2010) Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma. Oncogene 29:1909–1919PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Fernando AA, Dowing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838CrossRefPubMed Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Fernando AA, Dowing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838CrossRefPubMed
14.
Zurück zum Zitat Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20(8):460–469CrossRefPubMed Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20(8):460–469CrossRefPubMed
15.
Zurück zum Zitat Pallante P, Battista S, Pierantoni GM, Fusco A (2014) Deregulation of microRNA expression in thyroid neoplasias. Nat Rev Endocrinol 10:88–101CrossRefPubMed Pallante P, Battista S, Pierantoni GM, Fusco A (2014) Deregulation of microRNA expression in thyroid neoplasias. Nat Rev Endocrinol 10:88–101CrossRefPubMed
16.
Zurück zum Zitat Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN (2014) MicroRNA profile of poorly differentiated thyroid carcinomas–new diagnostic and prognostic insights. J Mol Endocrinol 52:181–189PubMedCentralCrossRefPubMed Dettmer MS, Perren A, Moch H, Komminoth P, Nikiforov YE, Nikiforova MN (2014) MicroRNA profile of poorly differentiated thyroid carcinomas–new diagnostic and prognostic insights. J Mol Endocrinol 52:181–189PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Jazdzewski K, Boguslawska J, Jendrzejewski J, Liyanarachchi S, Pachucki J, Wardyn KA, Nauman A, De la Chapelle A (2011) Thyroid hormone receptor β (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab 96:E546–E553PubMedCentralCrossRefPubMed Jazdzewski K, Boguslawska J, Jendrzejewski J, Liyanarachchi S, Pachucki J, Wardyn KA, Nauman A, De la Chapelle A (2011) Thyroid hormone receptor β (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab 96:E546–E553PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474CrossRefPubMed Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474CrossRefPubMed
19.
Zurück zum Zitat Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214CrossRefPubMed Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214CrossRefPubMed
20.
Zurück zum Zitat Sponziello M, Bruno R, Durante C, D’Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S, Russo D (2011) Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. Horm Metab Res 43:22–25CrossRefPubMed Sponziello M, Bruno R, Durante C, D’Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S, Russo D (2011) Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. Horm Metab Res 43:22–25CrossRefPubMed
21.
Zurück zum Zitat D’Agostino M, Sponziello M, Puppin C, Celano M, Maggisano V, Baldan F, Biffoni M, Bulotta S, Durante C, Filetti S, Damante G, Russo D (2014) Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. J Mol Endocrinol 52:121–131CrossRefPubMed D’Agostino M, Sponziello M, Puppin C, Celano M, Maggisano V, Baldan F, Biffoni M, Bulotta S, Durante C, Filetti S, Damante G, Russo D (2014) Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. J Mol Endocrinol 52:121–131CrossRefPubMed
22.
Zurück zum Zitat Sponziello M, Lavarone E, Pegolo E, Di Loreto C, Puppin C, Russo MA, Bruno R, Filetti S, Durante C, Russo D, Di Cristofano A, Damante G (2013) Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. Endocrinology 154:3043–3053PubMedCentralCrossRefPubMed Sponziello M, Lavarone E, Pegolo E, Di Loreto C, Puppin C, Russo MA, Bruno R, Filetti S, Durante C, Russo D, Di Cristofano A, Damante G (2013) Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. Endocrinology 154:3043–3053PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140:317–322CrossRefPubMed Davies L, Welch HG (2014) Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 140:317–322CrossRefPubMed
24.
Zurück zum Zitat Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S (2000) Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol 143:623–627CrossRefPubMed Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S (2000) Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol 143:623–627CrossRefPubMed
25.
Zurück zum Zitat Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M, Filetti S (2001) Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol 145:129–135CrossRefPubMed Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M, Filetti S (2001) Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol 145:129–135CrossRefPubMed
26.
Zurück zum Zitat Kogai T, Brent GA (2012) The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther 135:355–370PubMedCentralCrossRefPubMed Kogai T, Brent GA (2012) The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther 135:355–370PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM (2007) Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 3:260–269CrossRefPubMed Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM (2007) Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. Nat Clin Pract Endocrinol Metab 3:260–269CrossRefPubMed
28.
Zurück zum Zitat Fagin JA, Mitsiades N (2008) Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 22:955–969PubMedCentralCrossRefPubMed Fagin JA, Mitsiades N (2008) Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 22:955–969PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Russo D, Damante G, Puxeddu E, Durante C, Filetti S (2011) Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol 46:R73–R81CrossRefPubMed Russo D, Damante G, Puxeddu E, Durante C, Filetti S (2011) Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol 46:R73–R81CrossRefPubMed
31.
Zurück zum Zitat Galrão AL, Sodré AK, Camargo RY, Friguglietti CU, Kulcsar MA, Lima EU, Medeiros-Neto G, Rubio IG (2013) Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression. Endocrine 43:225–229CrossRefPubMed Galrão AL, Sodré AK, Camargo RY, Friguglietti CU, Kulcsar MA, Lima EU, Medeiros-Neto G, Rubio IG (2013) Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression. Endocrine 43:225–229CrossRefPubMed
32.
Zurück zum Zitat Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J (2002) Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87(3):1120–1128CrossRefPubMed Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J (2002) Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 87(3):1120–1128CrossRefPubMed
33.
Zurück zum Zitat Ciampi R, Nikiforov YE (2005) Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 16:163–172CrossRefPubMed Ciampi R, Nikiforov YE (2005) Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 16:163–172CrossRefPubMed
34.
Zurück zum Zitat Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D (2007) BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92(7):2840–2843CrossRefPubMed Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D (2007) BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92(7):2840–2843CrossRefPubMed
35.
Zurück zum Zitat Puxeddu E, Durante C, Avenia N, Filetti S, Russo D (2008) Clinical implication of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 19:138–145CrossRefPubMed Puxeddu E, Durante C, Avenia N, Filetti S, Russo D (2008) Clinical implication of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 19:138–145CrossRefPubMed
Metadaten
Titel
Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression
verfasst von
F. Rosignolo
V. Maggisano
M. Sponziello
M. Celano
C. R. T. Di Gioia
M. D’Agostino
L. Giacomelli
A. Verrienti
M. Dima
V. Pecce
C. Durante
Publikationsdatum
01.12.2015
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 12/2015
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-015-0309-4

Weitere Artikel der Ausgabe 12/2015

Journal of Endocrinological Investigation 12/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.